Anti-VDR (aa 318-427) polyclonal antibody

Name: Anti-VDR (aa 318-427) polyclonal antibody
SKU: DPAB-DC3180
Rating: 5 (1 reviews)

Mouse Anti-Human VDR (aa 318-427) polyclonal antibody for ELISA

COA

SDS

Datasheet

Summary

Specifications

Species Reactivity

Human

Immunogen

VDR (NP_000367, 318 a.a. ~ 427 a.a) partial recombinant protein with GST tag. The sequence is VGLKKLNLHEEEHVLLMAICIVSPDRPGVQDAALIEAIQDRLSNTLQTYIRCRHPPPGSH LLYAKMIQKLADLRSLNEEHSKQYRCLSFQPECSMKLTPLVLEVFGNEIS

Conjugate

Unconjugated

Target

Alternative Names

VDR; vitamin D (1,25- dihydroxyvitamin D3) receptor; NR1I1; PPP1R163; vitamin D3 receptor; 1,25-dihydroxyvitamin D3 receptor; vitamin D nuclear receptor variant 1; nuclear receptor subfamily 1 group I member 1; protein phosphatase 1, regulatory subunit 16

Entrez Gene ID

7421

UniProt ID

F1D8P8

Product Background

Antigen Description

This gene encodes the nuclear hormone receptor for vitamin D3. This receptor also functions as a receptor for the secondary bile acid lithocholic acid. The receptor belongs to the family of trans-acting transcriptional regulatory factors and shows sequence similarity to the steroid and thyroid hormone receptors. Downstream targets of this nuclear hormone receptor are principally involved in mineral metabolism though the receptor regulates a variety of other metabolic pathways, such as those involved in the immune response and cancer. Mutations in this gene are associated with type II vitamin D-resistant rickets. A single nucleotide polymorphism in the initiation codon results in an alternate translation start site three codons downstream. Alternative splicing results in multiple transcript variants encoding different proteins.

Pathway

Direct p53 effectors; Endocrine and other factor-regulated calcium reabsorption; Gene Expression; Mineral absorption

Citations

Have you cited DPAB-DC3180 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Decreased vitamin D receptor protein expression is associated with progression and poor prognosis of colorectal cancer patients

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY

Authors: Shi, Qi; Han, Xue-Ping; Yu, Jie; Peng, Hao; Chen, Yun-Zhao; Li, Feng; Cui, Xiao-Bin

Abstract

This study aimed to investigate vitamin D receptor (VDR) expression levels and evaluate their clinical significance in patients with colorectal cancer (CRC). VDR protein expression was validated by immunohistochemistry in 188 CRC tissues and 134 normal colorectal tissues. The associations between VDR expression and clinicopathologic characteristics, including prognostic outcomes, were analyzed. VDR expression in normal colorectal tissue was higher than that in CRC (83.6% versus 34.6%, P = 4.489 x 10(20)) and generated moderate diagnostic performance for CRC detection (AUC = 0.88, sensitivity = 0.87, specificity = 0.84). Low VDR expression was associated with invasion depth (P = 0.001) and poor survival in CRC (P = 0.031). Univariate Cox analysis demonstrated VDR expression (P = 0.036) was a significant prognostic predictor for survival in patients with CRC. Low VDR expression could be a valuable diagnostic and prognostic biomarker for CRC patients. Targeting VDR may offer a potential therapeutic strategy for blocking CRC.

Influence of Serum Vitamin D Level in the Response of Actinic Keratosis to Photodynamic Therapy with Methylaminolevulinate

JOURNAL OF CLINICAL MEDICINE

Authors: Moreno, Ricardo; Najera, Laura; Mascaraque, Marta; Juarranz, Angeles; Gonzalez, Salvador; Gilaberte, Yolanda

Abstract

In mouse models of squamous cell carcinoma, pre-treatment with calcitriol prior to photodynamic therapy with aminolevulinic acid (ALA) enhances tumor cell death. We have evaluated the association between vitamin D status and the response of actinic keratoses to photodynamic therapy with methylaminolevulinate. Twenty-five patients with actinic keratoses on the head received one session of photodynamic therapy with methylaminolevulinate. Biopsies were taken at baseline and six weeks after treatment. Immuno-histochemical staining was performed for VDR, P53, Ki67 and beta-catenin. Basal serum 25(OH)D levels were determined. Cases with a positive histological response to treatment had significantly higher serum 25(OH)D levels (26.96 (SD 7.49) ngr/mL) than those without response (18.60 (SE 7.49) ngr/mL) (p = 0.05). Patients with a complete clinical response displayed lower basal VDR expression (35.71% (SD 19.88)) than partial responders (62.78% (SD 16.735)), (p = 0.002). Our results support a relationship between vitamin D status and the response of actinic keratoses to photodynamic therapy with methylaminolevulinate.